News

Cloud-based drug design and development company, Cloud Pharmaceuticals, Inc., recently announced it has signed with THERAMetrics holding AG to collaborate on breakthrough treatments for orphan central nervous system (CNS) diseases and other indications. This strategic collaboration has as its primary points of interest Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy…

New research out of London has identified specific, highly connected brain regions, known as “rich club brain regions” that may be vulnerable in Huntington’s disease and possibly in other diseases in which there is progressive deterioration of brain cells (neurodegenerative diseases). The article, titled “Selective vulnerability of Rich…

Bioinformatics, a field that enables powerful analysis of large amounts of data, is being applied to Huntington’s disease to find potential candidate molecules that play a role in pathogenesis. Researchers have conducted high throughput screens of genetic information, and this information is now being deciphered by different computer programs to…

Germany and UK-based researchers have found that a surgical implantation procedure known as pallidal deep brain stimulation was safe when placed into the brain for the reduction of movement problems in Huntington’s disease. The study could allow for more research examining the effectiveness of the technique in larger groups of people with the condition.